[1] Rhodes A, Evans LE, Alhazzani, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016[J]. Crit Care Med, 2017, 45: 486-552. doi: 10.1097/CCM.0000000000002255 |
[2]
|
Rhodes A, Evans LE, Alhazzani, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016[J]. Intensive Care Med, 2017, 43: 304-377. doi: 10.1007/s00134-017-4683-6 |
[3]
|
Gilbert DN, Kalil AC, Klompas M, et al. Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines.[J]. Clin Infect Dis, 2018, 66:1631-1635. doi: 10.1093/cid/cix997 |
[4]
|
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)[J]. JAMA, 2016, 315: 801-810. doi: 10.1001/jama.2016.0287 |
[5]
|
Klein Klouwenberg PM, Cremer OL, van Vught LA, et al. Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study[J]. Crit Care, 2015, 19: 319. doi: 10.1186/s13054-015-1035-1 |
[6]
|
Garcia RA, Spitzer ED, Beaudry J, et al. Multidisciplinary team review of best practices for collection and handling of blood cultures to determine effective interventions for increasing the yield of true-positive bacteremias, reducing contamination, and eliminating false-positive central line-associated bloodstream infections[J]. Am J Infect Control, 2015, 43: 1222-1237. doi: 10.1016/j.ajic.2015.06.030 |
[7]
|
Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009, 49: 1-45. doi: 10.1086/599376 |
[8]
|
Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock[J]. Crit Care Med, 2006, 34: 1589-1596. doi: 10.1097/01.CCM.0000217961.75225.E9 |
[9]
|
Seymour CW, Foster G, Prescott HC, et al. Time to Treatment and Mortality during Mandated Emergency Care for Sepsis[J]. N Engl J Med, 2017, 376: 2235-2244. doi: 10.1056/NEJMoa1703058 |
[10]
|
National Quality Forum. NQF #0500 Severe Sepsis and Septic Shock: Management Bundle[EB/OL].http://www.quality-forum.org/WorkArea/linkit.aspx?inkIdentifier=id&ItemID=71548. |
[11]
|
Institute for Healthcare Improvement. Severe sepsis bundles[EB/OL].http://www.ihi.org/resources/Pages/Tools/SevereSepsisBundles.aspx. |
[12]
|
Kalil AC, Johnson DW, Lisco SJ, et al.Early Goal-Directed Therapy for Sepsis: A Novel Solution for Discordant Survival Outcomes in Clinical Trials[J]. Crit Care Med, 2017, 45: 607-614. doi: 10.1097/CCM.0000000000002235 |
[13]
|
Singer M. Antibiotics for Sepsis-Does Each Hour Really Count? Or is it Incestuous Amplification?[J]. Am J Respir Crit Care Med, 2017, 196: 800-802. doi: 10.1164/rccm.201703-0621ED |
[14]
|
Klompas M. Monotherapy Is Adequate for Septic Shock Due to Gram-Negative Organisms[J]. Crit Care Med, 2017, 45:1930-1932. doi: 10.1097/CCM.0000000000002678 |
[15]
|
Brunkhorst FM, Oppert M, Marx G, et al. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial[J]. JAMA, 2012, 307: 2390-2399. doi: 10.1001/jama.2012.5833 |
[16]
|
Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society[J]. Clin Infect Dis, 2016, 63: e61-e111. doi: 10.1093/cid/ciw353 |
[17]
|
Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial[J]. Lancet, 2010, 375: 463-474. doi: 10.1016/S0140-6736(09)61879-1 |
[18]
|
de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial[J]. Lancet Infect Dis, 2016, 16: 819-827. doi: 10.1016/S1473-3099(16)00053-0 |
[19]
|
Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America[J]. Clin Infect Dis, 2010, 50: 133-164. doi: 10.1086/649554 |